Skip to main content
SpringerLink
Log in

18F-FET

  • Chapter
  • First Online:
Radiopharmaceuticals

  • 981 Accesses

Abstract

18F-FET is a radiolabelled amino acid that may be used as PET radiopharmaceutical in neuro-oncology. 18F-FET PET has been demonstrated to be useful in the differential diagnosis between brain tumours and non-neoplastic lesions and between low-grade and high-grade gliomas. Integration of 18F-FET PET into surgical planning allows better delineation of the extent of resection beyond margins visible with standard MRI. For biopsy planning, 18F-FET PET is particularly useful in identifying malignant foci within non-contrast-enhancing gliomas. 18F-FET PET may also improve the radiation therapy planning in patients with gliomas. This metabolic imaging method may be useful to evaluate treatment response in patients with gliomas and it improves the differential diagnosis between brain tumours recurrence and post-treatment changes. Furthermore, 18F-FET PET may provide useful prognostic information in high-grade gliomas.

Overall, based on literature data 18F-FET PET may provide additional diagnostic information compared to standard MRI in neuro-oncology.

Authors declare they have obtained permission for any previously published material used in their chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

18F-FDG:

Fluorine-18 fluorodeoxyglucose

18F-FDOPA:

Fluorine-18 fluorodihydroxyphenylalanine

18F-FET:

Fluorine-18 fluoroethyltyrosine

18F-FLT:

Fluorine-18 fluorothymidine

CT:

Computed tomography

EANO:

European Association for Neuro-Oncology

LBR:

Lesion-to-background ratio

MBq:

MegaBecquerel

MRI:

Magnetic resonance imaging

PET:

Positron emission tomography

RANO:

Response Assessment in Neuro-Oncology (RANO)

Sv:

Sievert

References

  1. Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57(6):853–6.

    Article  CAS  Google Scholar 

  2. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40(1):205–12.

    CAS  PubMed  Google Scholar 

  3. Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40(8):1367–73.

    CAS  PubMed  Google Scholar 

  4. Pauleit D, Floeth F, Herzog H, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30(4):519–24.

    Article  CAS  Google Scholar 

  5. Tang G, Wang M, Tang X, et al. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl Radiat Isot. 2003;58(2):219–25.

    Article  CAS  Google Scholar 

  6. Vander Borght T, Asenbaum S, Bartenstein P, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374–80.

    Article  CAS  Google Scholar 

  7. Muoio B, Giovanella L, Treglia G. Recent developments of 18F-FET PET in neuro-oncology. Curr Med Chem. 2018;25(26):3061–73.

    Article  CAS  Google Scholar 

  8. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–208.

    Article  CAS  Google Scholar 

  9. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med. 2012;53(2):207–14.

    Article  CAS  Google Scholar 

  10. Heinzel A, Stock S, Langen KJ, et al. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging. 2012;39(7):1089–96.

    Article  Google Scholar 

  11. Munck Af Rosenschold P, Costa J, Engelholm SA, et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro Oncol. 2015;17(5):757–63.

    Article  CAS  Google Scholar 

  12. Muoio B, Treglia G, Reinert M, et al. Diagnostic performance of static 18F-fluoroethyl-L-tyrosine positron emission tomography parameters to differentiate recurrent brain tumours from non-neoplastic treatment-related changes: a meta-analysis. Neuro Oncol. 2016;18.(Suppl 4:iv9.

    Article  Google Scholar 

  13. Gempt J, Bette S, Ryang YM, et al. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. Eur J Radiol. 2015;84(5):955–62.

    Article  Google Scholar 

  14. Henriksen OM, Larsen VA, Muhic A, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43(1):103–12.

    Article  CAS  Google Scholar 

  15. Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81(4):1049–58.

    Article  CAS  Google Scholar 

  16. Roelcke U, Bruehlmeier M, Hefti M, et al. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas. Clin Nucl Med. 2012;37(1):e1–3.

    Article  Google Scholar 

  17. Jeong SY, Lim SM. Comparison of 3′-deoxy-3′-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol. 2012;39(7):977–81.

    Article  CAS  Google Scholar 

  18. Nowosielski M, DiFranco MD, Putzer D, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One. 2014;9(4):e95830.

    Article  Google Scholar 

  19. Kratochwil C, Combs SE, Leotta K, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014;16(3):434–40.

    Article  CAS  Google Scholar 

  20. Lapa C, Linsenmann T, Monoranu CM, et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014;55(10):1611–6.

    Article  CAS  Google Scholar 

  21. Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18(3):426–34.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Conflicts of Interest: The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona and Lugano, Switzerland

    Giorgio Treglia & Luca Giovanella

  2. Health Technology Assessment Unit, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

    Giorgio Treglia

  3. Department of Nuclear Medicine and Molecular Imaging, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland

    Giorgio Treglia

  4. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

    Barbara Muoio

Authors
  1. Giorgio Treglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Muoio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Giovanella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giorgio Treglia .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine and Theranostics, Mariano Santo Hospital, Cosenza, Italy

    Ferdinando Calabria

  2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

    Orazio Schillaci

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Treglia, G., Muoio, B., Giovanella, L. (2020). 18F-FET. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27779-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27778-9

  • Online ISBN: 978-3-030-27779-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation